Stock listing

IMTX Stock Price, News, Filings & Events — Immatics N.v.

Selected listing: IMTX · BOATS · USD · US

This page tracks Immatics N.v.'s IMTX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IMTX:BOATS. IMTX:BOATS is the stock-level entry point for investors researching Immatics N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Immatics N.V. is a public company traded under the ticker IMTX in the American market. The company has a market capitalization of approximately $1.22 billion. Immatics focuses on developing innovative cancer immunotherapies.

IMTX:BOATSUSDUSUpdated August 21, 2026
Immatics N.v. logo
Ticker
IMTX:BOATS
Asset type
Stock
Market cap
$1.22B
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
BOATS
Currency
USD

Immatics N.v. IMTX:BOATS stock context

This page tracks Immatics N.v.'s IMTX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IMTX:BOATS. IMTX:BOATS is the stock-level entry point for investors researching Immatics N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Immatics N.V. is a public company traded under the ticker IMTX in the American market. The company has a market capitalization of approximately $1.22 billion. Immatics focuses on developing innovative cancer immunotherapies.

Latest news from Immatics N.v.

All Immatics N.v. news →

Research Immatics N.v.

Alternate listings